Kodiak Sciences Inc.
KOD
Rank in Stocks
#3149
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Share Price
$90.83
Last synced: 2026-10-19
Market Cap
$5.71B
Change (1 day)
5.92%
Change (1 year)
413.16%
Country
US
Trade Kodiak Sciences Inc. (KOD)
Category
Healthcare
Stock split history for Kodiak Sciences Inc. (KOD)
Kodiak Sciences Inc. stock (symbol: KOD) underwent a total of 1 stock splits.
The most recent stock split occurred on Feb 23, 2022.
One KOD share bought prior to Feb 23, 2022 would equal to 5 KOD shares today.
The most recent stock split occurred on Feb 23, 2022.
One KOD share bought prior to Feb 23, 2022 would equal to 5 KOD shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| 2022-02-23 | 5:1 | x5 | x5 |
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
